Supplementary Data from Fimepinostat Impairs NFκB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma

Dan Wang,Kun Yan,Hongxing Yu,Haocheng Li,Wei Zhou,Yaqiang Hong,Shuning Guo,Yi Wang,Cheng Xu,Changcun Pan,Yujie Tang,Nian Liu,Wei Wu,Liwei Zhang,Qiaoran Xi

DOI: https://doi.org/10.1158/0008-5472.25224448

2024-01-01

Abstract:Supplementary Figures 1-7; Supplementary Tables 1-8

What problem does this paper attempt to address?

Data from Fimepinostat Impairs NFκB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma

Dan Wang,Kun Yan,Hongxing Yu,Haocheng Li,Wei Zhou,Yaqiang Hong,Shuning Guo,Yi Wang,Cheng Xu,Changcun Pan,Yujie Tang,Nian Liu,Wei Wu,Liwei Zhang,Qiaoran Xi

DOI: https://doi.org/10.1158/0008-5472.can-23-0394

IF: 11.2

2024-01-01

Cancer Research

Abstract:Abstract Diffuse intrinsic pontine glioma (DIPG) is the most aggressive pediatric brain tumor, and the oncohistone H3.3K27M mutation is associated with significantly worse clinical outcomes. Despite extensive research efforts, effective approaches for treating DIPG are lacking. Through drug screening, we identified the combination of gemcitabine and fimepinostat as a potent therapeutic intervention for H3.3K27M DIPG. H3.3K27M facilitated gemcitabine-induced apoptosis in DIPG, and gemcitabine stabilized and activated p53, including increasing chromatin accessibility for p53 at apoptosis-related loci. Gemcitabine simultaneously induced a prosurvival program in DIPG through activation of RELB-mediated NFκB signaling. Specifically, gemcitabine induced the transcription of long terminal repeat elements, activated cGAS-STING signaling, and stimulated noncanonical NFκB signaling. A drug screen in gemcitabine-treated DIPG cells revealed that fimepinostat, a dual inhibitor of HDAC and PI3K, effectively suppressed the gemcitabine-induced NFκB signaling in addition to blocking PI3K/AKT activation. Combination therapy comprising gemcitabine and fimepinostat elicited synergistic antitumor effects in vitro and in orthotopic H3.3K27M DIPG xenograft models. Collectively, p53 activation using gemcitabine and suppression of RELB-mediated NFκB activation and PI3K/AKT signaling using fimepinostat is a potential therapeutic strategy for treating H3.3K27M DIPG. Significance: Gemcitabine activates p53 and induces apoptosis to elicit antitumor effects in H3.3K27M DIPG, which can be enhanced by blocking NFκB and PI3K/AKT signaling with fimepinostat, providing a synergistic combination therapy for DIPG.
Fimepinostat impairs NFκB and PI3K/AKT signaling and enhances gemcitabine efficacy in H3K27M-mutated diffuse intrinsic pontine glioma

Dan Wang,Kun Yan,Hongxing Yu,Haocheng Li,Wei Zhou,Yaqiang Hong,Shuning Guo,Yi Wang,Cheng Xu,Changcun Pan,Yujie Tang,Nian Liu,Wei Wu,Liwei Zhang,Qiaoran Xi

DOI: https://doi.org/10.1158/0008-5472.can-23-0394

IF: 11.2

2023-12-15

Cancer Research

Abstract:Diffuse intrinsic pontine glioma (DIPG) is the most aggressive pediatric brain tumor, and the oncohistone H3.3K27M mutation is associated with significantly worse clinical outcomes. Despite extensive research efforts, effective approaches for treating DIPG are lacking. Through drug screening, we identified the combination of gemcitabine and fimepinostat as a potent therapeutic intervention for H3.3K27M DIPG. H3.3K27M facilitated gemcitabine-induced apoptosis in DIPG, and gemcitabine stabilized and activated p53, including increasing chromatin accessibility for p53 at apoptosis-related loci. Gemcitabine simultaneously induced a pro-survival program in DIPG through activation of RELB-mediated NFκB signaling. Specifically, gemcitabine induced the transcription of long terminal repeat elements, activated cGAS-STING signaling, and stimulated non-canonical NFκB signaling. A drug screen in gemcitabine-treated DIPG cells revealed that fimepinostat, a dual inhibitor of HDAC and PI3K, effectively suppressed the gemcitabine-induced NFκB signaling in addition to blocking PI3K/AKT activation. Combination therapy comprising gemcitabine and fimepinostat elicited synergistic anti-tumor effects in vitro and in orthotopic H3.3K27M DIPG xenograft models. Collectively, p53 activation using gemcitabine and suppression of RELB-mediated NFκB activation and PI3K/AKT signaling using fimepinostat is a potential therapeutic strategy for treating H3.3K27M DIPG.

oncology
Fimepinostat Impairs NF-κB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma.

Dan Wang,Kun Yan,Hongxing Yu,Haocheng Li,Wei Zhou,Yaqiang Hong,Shuning Guo,Yi Wang,Cheng Xu,Changcun Pan,Yujie Tang,Nian Liu,Wei Wu,Liwei Zhang,Qiaoran Xi

DOI: https://doi.org/10.1158/0008-5472.CAN-23-0394

IF: 11.2

2024-01-01

Cancer Research

Abstract:Diffuse intrinsic pontine glioma (DIPG) is the most aggressive pediatric brain tumor, and the oncohistone H3.3K27M mutation is associated with significantly worse clinical outcomes. Despite extensive research efforts, effective approaches for treating DIPG are lacking. Through drug screening, we identified the combination of gemcitabine and fimepinostat as a potent therapeutic intervention for H3.3K27M DIPG. H3.3K27M facilitated gemcitabine-induced apoptosis in DIPG, and gemcitabine stabilized and activated p53, including increasing chromatin accessibility for p53 at apoptosis-related loci. Gemcitabine simultaneously induced a prosurvival program in DIPG through activation of RELB-mediated NF-κB signaling. Specifically, gemcitabine induced the transcription of long terminal repeat elements, activated cGAS-STING signaling, and stimulated noncanonical NF-κB signaling. A drug screen in gemcitabine-treated DIPG cells revealed that fimepinostat, a dual inhibitor of HDAC and PI3K, effectively suppressed the gemcitabine-induced NF-κB signaling in addition to blocking PI3K/AKT activation. Combination therapy comprising gemcitabine and fimepinostat elicited synergistic antitumor effects in vitro and in orthotopic H3.3K27M DIPG xenograft models. Collectively, p53 activation using gemcitabine and suppression of RELB-mediated NF-κB activation and PI3K/AKT signaling using fimepinostat is a potential therapeutic strategy for treating H3.3K27M DIPG. SIGNIFICANCE:Gemcitabine activates p53 and induces apoptosis to elicit antitumor effects in H3.3K27M DIPG, which can be enhanced by blocking NF-κB and PI3K/AKT signaling with fimepinostat, providing a synergistic combination therapy for DIPG.
Supplementary Figure S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma

Qingsheng Xu,Kaiyuan Huang,Xiangqi Meng,Yuxiang Weng,Luyuan Zhang,Linghao Bu,Xiujue Zheng,Jinquan Cai,Renya Zhan,Qun Chen

DOI: https://doi.org/10.1158/1078-0432.24228964

2023-01-01

Abstract:A-B. Kaplan-Meier plots of progression-free survival and overall survival (Full analysis set). The x-axes indicated times since enrollment.
Perifosine inhibits S6K1–Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency

Ying Xin,Xiang-di Shen,Long Cheng,De-fei Hong,Bin Chen

DOI: https://doi.org/10.1007/s00280-014-2397-9

2014-01-01

Cancer Chemotherapy and Pharmacology

Abstract:Purpose The pancreatic cancer has extremely low overall 5-year survival, and gemcitabine is the only approved single agent for pancreatic cancer treatment. Methods In the present study, we investigated the potential effect of perifosine, a novel Akt inhibitor on gemcitabine-induced anti-pancreatic cancer effect both in vivo and in vitro. Results We showed that sub-cytotoxic low concentration of perifosine dramatically enhanced gemcitabine-induced cytotoxicity in cultured pancreatic cancer cells. Perifosine inhibited Akt–mammalian target of rapamycin and Erk–mitogen-activated protein kinase activation in pancreatic cancer cells. Meanwhile, perifosine suppressed the hedgehog signaling, as it inhibited glioma-associated oncogenes (Gli) 1 activation and decreased its target protein patched 1 (PTCH1) expression. Our data demonstrated that perifosine blocked p70S6K1 (S6K1) activation, thus disrupting S6K1–Gli1 association and subsequent Gli1 activation. The reduction of S6K1 or Gli1 expression by target siRNAs inhibited PTCH1 expression and enhanced gemcitabine-induced cytotoxicity in pancreatic cancer cells. Significantly, perifosine dramatically enhanced gemcitabine-mediated antitumor effect in a PANC-1 xenograft severe combined immunodeficiency mice model. Conclusions In summary, we conclude that perifosine sensitizes gemcitabine-mediated anti-pancreatic cancer efficiency through regulating multiple signaling pathways.
Fisetin inhibits proliferation of pancreatic adenocarcinoma by inducing DNA damage via RFXAP/KDM4A-dependent histone H3K36 demethylation

Guoping Ding,Xiaodong Xu,Dan Li,Yuhao Chen,Weimin Wang,Dongnan Ping,Shengnan Jia,Liping Cao

DOI: https://doi.org/10.1038/s41419-020-03019-2

2020-01-01

Abstract:Pancreatic adenocarcinoma (PDAC) is an extremely malignant tumor that is associated with low survival rates. Fisetin is a natural flavonoid that shows diverse antitumor effects, including DNA damage, in various cancers. Increasing studies have demonstrated that epigenetic modifications play critical roles in DNA-damage response. However, the epigenetic regulation mechanism of fisetin in cancers is hardly studied. RFXAP is a critical transcription factor for MHC II molecules, however, its transcriptional role in PDAC is poorly understood. The anti-PDAC effect of fisetin was measured by CCK-8, flow cytometry, xenograft tumor nude mice model. DNA-damage levels were examined by immunofluorescence. Bioinformatics analysis was used to examine the expression of RFXAP and other genes involved in DNA-damage response. ChIP sequencing was used to explore the transcriptional role of RFXAP. The expression of target gene KDM4A was measured by qRT-PCR and western blots. KDM4A promoter activity was analyzed using dual-luciferase reporter assay. RFXAP overexpressing or silencing of PDAC cells was used to explore the effect of RFXAP in DNA damage induced by fisetin. We found that fisetin inhibited cell proliferation and induced DNA damage and S-phase arrest in PDAC. Expression of RFXAP and other DNA-damage response genes were upregulated by fisetin. We revealed that RFXAP expression was relatively low in PDAC and correlated with tumor stage and poor prognosis. Then we explored the transcriptional role of RFXAP and found that RFXAP targeted KDM4A , a special demethylase specific for tri- and dimethylated histone H3K36. We found that overexpression of RFXAP upregulated KDM4A and attenuated methylation of H3K36, thereby impairing DNA repair and enhancing the DNA damage induced by fisetin, while RFXAP silencing showed the opposite effect. We also found the function of fisetin in enhancing the effect of chemotherapy on pancreatic cancer cells. Our findings revealed that fisetin induced DNA damage via RFXAP/KDM4A-dependent histone H3K36 demethylation, thus causing inhibition of proliferation in PDAC.
Supplementary Figures 1 - 5, Tables 1 - 2 from Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers

Pablo D. Garcia,John L. Langowski,Yingyun Wang,Min Chen,Joseph Castillo,Christie Fanton,Marjorie Ison,Tatiana Zavorotinskaya,Yumin Dai,Jing Lu,Xiao-Hong Niu,Stephen Basham,Julie Chan,Jianjun Yu,Michael Doyle,Paul Feucht,Robert Warne,Jamie Narberes,Tiffany Tsang,Christine Fritsch,Audrey Kauffmann,Estelle Pfister,Peter Drueckes,Joerg Trappe,Christopher Wilson,Wooseok Han,Jiong Lan,Gisele Nishiguchi,Mika Lindvall,Cornelia Bellamacina,J. Alex Aycinena,Richard Zang,Jocelyn Holash,Matthew T. Burger

DOI: https://doi.org/10.1158/1078-0432.22452158

2023-01-01

Abstract:PDF file - 346KB, Supplementary Figure 1. Normal vs. Tumor expression of PIM kinases mRNA across 17 tissue types. Supplementary Figure 2. Comparison of LGB321 on-target activity vs. Previously described pan-PIM inhibitor. Supplementary Figure 3. KINOMESCANTM of 1 mu M LGB321. Supplementary Figure 4. Biochemical and cellular selectivity of the LGB321 PIM inhibitor series towards GSK3 beta. Supplementary Figure 5. LGB321 does not inhibit EGFR signaling in HCC1954 cells. Supplementary Table 1. Sensitivity to LGB321 and Erlotinib of Lung Cells in the CCLE. Supplementary Table 2. Sensitivity to LGB321 of hematological malignacies cell lines.
Post-translational Modification of CDK1–STAT3 Signaling by Fisetin Suppresses Pancreatic Cancer Stem Cell Properties

Xiaodong Xu,Yimin Ding,Junbin Jin,Chengjie Xu,Wenyi Hu,Songtao Wu,Guoping Ding,Rui Cheng,Liping Cao,Shengnan Jia

DOI: https://doi.org/10.1186/s13578-023-01118-z

2023-01-01

Cell & Bioscience

Abstract:BACKGROUND:Pancreatic cancer stem cells (CSCs) promote pancreatic ductal adenocarcinoma (PDAC) tumorigenesis and chemoresistance. Cyclin-dependent kinase 1 (CDK1) plays an important role in tumor initiation in other tumors, but the function of CDK1 in PDAC remains unclear. Fisetin is a bioactive flavonoid with anti-tumor properties in multiple tumors, while its function in CSCs remains elusive.RESULTS:In this study, we demonstrated that CDK1 was correlated with prognosis and was highly expressed in pancreatic cancer tissue and gemcitabine-resistant cells. Silencing CDK1 impaired tumor stemness and reduced a subset of CSCs. We found that fisetin blocked the kinase pocket domain of CDK1 and inhibited pancreatic CSC characteristics. Using acetylation proteomics analysis and phosphorylation array assay, we confirmed that fisetin reduced CDK1 expression and increased CDK1 acetylation at lysine 33 (K33), which resulted in the suppression of CDK1 phosphorylation. Silencing CDK1 or STAT3 suppressed tumor stemness properties, while overexpressing CDK1 or STAT3 showed the opposite effect. Mutation or acetylation of CDK1 at K33 weakened STAT3 phosphorylation at Y705, impairing the expression of stem-related genes and pancreatic cancer stemness. In addition, lack of histone deacetylase 3 (HDAC3), which deacetylates CDK1, contributed to weakening STAT3 phosphorylation by regulating the post-translational modification of CDK1, thereby decreasing the stemness of PDAC. Moreover, our results revealed that fisetin enhanced the effect of gemcitabine through eliminating a subpopulation of pancreatic CSCs by inhibiting the CDK1-STAT3 axis in vitro and in vivo.CONCLUSION:Our findings highlight the role of post-translational modifications of CDK1-STAT3 signaling in maintaining cancer stemness of PDAC, and indicated that targeting the CDK1-STAT3 axis with inhibitors such as fisetin is a potential therapeutic strategy to diminish drug resistance and eliminate PDAC.
Supplementary Figures S1-S4 from Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer

Ivan S. Donev,Wei Wang,Tadaaki Yamada,Qi Li,Shinji Takeuchi,Kunio Matsumoto,Takao Yamori,Yasuhiko Nishioka,Saburo Sone,Seiji Yano

DOI: https://doi.org/10.1158/1078-0432.22442205

2023-01-01

Abstract:Supplementary Figures S1-S4.
Supplementary Materials and Methods from Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1–MAPK Interaction

Xin Jin,Yunqian Pan,Liguo Wang,Tao Ma,Lizhi Zhang,Amy H. Tang,Daniel D. Billadeau,Heshui Wu,Haojie Huang

DOI: https://doi.org/10.1158/0008-5472.22414161

2023-01-01

Abstract:Supplementary Materials and Methods
Legend for Supplementary Figures from Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma

Tongxin Liu,Quanquan Sun,Qi Li,Hua Yang,Yuqin Zhang,Rong Wang,Xiaoshan Lin,Dong Xiao,Yawei Yuan,Longhua Chen,Wei Wang

DOI: https://doi.org/10.1158/1535-7163.22502823

2023-01-01

Abstract:Supplementary Figure legends
Supplementary Figures 1-9, Supplementary Table 1 from Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib

Zhaohui Wang,Cheng Xu,Bill H. Diplas,Casey J. Moure,Chin-Pu Jason Chen,Lee H. Chen,Changzheng Du,Huishan Zhu,Paula K. Greer,Liwei Zhang,Yiping He,Matthew S. Waitkus,Hai Yan

DOI: https://doi.org/10.1158/1541-7786.22513743

2023-01-01

Abstract:Supplementary Fig. 1. Confirmation of SF7761 derived PPM1D-/- clones by Sanger sequencing. Supplementary Fig. 2. Effect of DNA repair inhibitors on cell viability in SF7761 parental and PPM1D-/- clones. Supplementary Fig. 3. GSK2830371 treatment synergizes with olaparib in PPM1D-mutant DIPG cells. Supplementary Fig. 4. Combination treatment low-dose GSK2830371 and olaparib in TT10714. Supplementary Fig. 5. Matrix plots representation of relative cell viabilities treated with indicated concentrations of olaparib and GSK2830371 for 7 days. Supplementary Fig. 6. 3D spheroid invasion assay performed to assess the growth and invasive potential of TT10714 cells upon single-agent or combination treatments. Supplementary Fig. 7. 3D spheroid invasion assay performed to assess 3D spheroid growth and invasive potential of SF7761 cells upon single-agent or combination treatments. Supplementary Fig. 8. 3D spheroid invasion assay performed to assess 3D spheroid growth and invasive potential of HSJD-DIPG-007 cells upon single-agent or combination treatments. Supplementary Fig. 9. Analysis of 53BP1 foci in response to PPM1D genetic inhibition and olaparib treatment. Supplementary Table 1. Oligos and Primer sequences.
Supplementary Figure 2 from Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1–MAPK Interaction

Xin Jin,Yunqian Pan,Liguo Wang,Tao Ma,Lizhi Zhang,Amy Tang,Daniel D. Billadeau,Heshui Wu,Haojie Huang

DOI: https://doi.org/10.1158/0008-5472.22414164

2023-01-01

Abstract:Assessment of the effect of gemcitabine treatment on the cell cycle and interaction of IQGAP1 and ERK1/2 in PANC-1 cells.
Supplementary Figure Legends from Mir-124 Inhibits STAT3 Signaling to Enhance T Cell–Mediated Immune Clearance of Glioma

Jun Wei,Fei Wang,Ling-Yuan Kong,Shuo Xu,Tiffany Doucette,Sherise D. Ferguson,Yuhui Yang,Kayla McEnery,Krishan Jethwa,Olsi Gjyshi,Wei Qiao,Nicholas B. Levine,Frederick F. Lang,Ganesh Rao,Gregory N. Fuller,George A. Calin,Amy B. Heimberger

DOI: https://doi.org/10.1158/0008-5472.22394862.v1

2023-01-01

Abstract:Supplementary Figure Legends - PDF file 70K, Supplementary Figure Legends
Additional File 14 of M6a Eraser FTO Impairs Gemcitabine Resistance in Pancreatic Cancer Through Influencing NEDD4 Mrna Stability by Regulating the PTEN/PI3K/AKT Pathway

Kai Lin,Endi Zhou,Tongguo Shi,Siqing Zhang,Jinfan Zhang,Ziruo Zheng,Yuetian Pan,Wentao Gao,Yabin Yu

DOI: https://doi.org/10.6084/m9.figshare.24002811

2023-01-01

Abstract:Additional file 14: Supplementary file 3. RNA-seq after FTO overexpression in CFPAC-GM cells.
Supplementary Data from CDK4/6 Inhibition Enhances Oncolytic Virus Efficacy by Potentiating Tumor-Selective Cell Killing and T-cell Activation in Refractory Glioblastoma

Jingshu Xiao,Jiaming Liang,Junjie Fan,Panpan Hou,Xiaodong Li,Haipeng Zhang,Kai Li,Lang Bu,Ping Li,Miao He,Yongheng Zhong,Liping Guo,Penghui Jia,Qiaoqiao Xiao,Junyu Wu,Hong Peng,Chunmei Li,Fan Xing,Deyin Guo

DOI: https://doi.org/10.1158/0008-5472.22431786.v1

2023-01-01

Abstract:Supplementary Data from CDK4/6 Inhibition Enhances Oncolytic Virus Efficacy by Potentiating Tumor-Selective Cell Killing and T-cell Activation in Refractory Glioblastoma
Supplementary Data from Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response

Shilpak Chatterjee,Paramita Chakraborty,Anusara Daenthanasanmak,Supinya Iamsawat,Gabriela Andrejeva,Libia A. Luevano,Melissa Wolf,Uday Baliga,Carsten Krieg,Craig C. Beeson,Meenal Mehrotra,Elizabeth G. Hill,Jeffery C. Rathmell,Xue-Zhong Yu,Andrew S. Kraft,Shikhar Mehrotra

DOI: https://doi.org/10.1158/1078-0432.22469031

2023-01-01

Abstract:Supplementary Figures and Figure Legends
Supplementary Figure S3 from Protein Kinase B (PKB/AKT) Protects IDH-Mutated Glioma from Ferroptosis Via Nrf2

Yang Liu,Fu-Ju Chou,Fengchao Lang,Meili Zhang,Hua Song,Wei Zhang,Dionne L. Davis,Nicole J. Briceno,Yang Zhang,Patrick J. Cimino,Kareem A. Zaghloul,Mark R. Gilbert,Terri S. Armstrong,Chunzhang Yang

DOI: https://doi.org/10.1158/1078-0432.22489814

2023-01-01

Abstract:(A) Phase contrast images showed the cytotoxicity of TMZ (400 mM)/ipatasertib (Ipa, 2 mM) combination treatment in the brain tumor-initiating cells (BTICs). A ferroptosis inhibitor, Ferrstain-1 (Ferr-1, 5 mM), was used to rescue the ferroptotic cell death. Bar = 100 mM. (B) Representative flow cytometric analysis of live/dead staining in BTICs in response to TMZ/Ipa treatment. (C) Statistical analysis of dead/live cell ratio in BTICs. (D) The limiting dilution assay evaluated the frequency of generating spheres in GSC827 and TSC603 after receiving TMZ/Ipa treatment. **p < 0.01.
Supplementary Table S2 from Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1–MAPK Interaction

Xin Jin,Yunqian Pan,Liguo Wang,Tao Ma,Lizhi Zhang,Amy H. Tang,Daniel D. Billadeau,Heshui Wu,Haojie Huang

DOI: https://doi.org/10.1158/0008-5472.22414155

2023-01-01

Abstract:FBP1-associated proteins identified by tandem affinity purification and mass spectrometry
Supplementary Data from Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma

Cho-Hao Lin,Khadija H. Elkholy,Nissar Ahmad Wani,Li Ding,Ping Hu,Juan M. Barajas,Lianbo Yu,Xiaoli Zhang,Samson T. Jacob,Wasif N. Khan,Xuefeng Bai,Anne M. Noonan,Kalpana Ghoshal

DOI: https://doi.org/10.1158/1535-7163.22506318

2023-01-01

Abstract:Supplementary figures and tables

Supplementary Data from Fimepinostat Impairs NF­κB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma

Data from Fimepinostat Impairs NF­κB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma

Fimepinostat impairs NF­κB and PI3K/AKT signaling and enhances gemcitabine efficacy in H3K27M-mutated diffuse intrinsic pontine glioma

Fimepinostat Impairs NF-κB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma.

Supplementary Figure S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma

Perifosine inhibits S6K1–Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency

Fisetin inhibits proliferation of pancreatic adenocarcinoma by inducing DNA damage via RFXAP/KDM4A-dependent histone H3K36 demethylation

Supplementary Figures 1 - 5, Tables 1 - 2 from Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers

Post-translational Modification of CDK1–STAT3 Signaling by Fisetin Suppresses Pancreatic Cancer Stem Cell Properties

Supplementary Figures S1-S4 from Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer

Supplementary Materials and Methods from Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1–MAPK Interaction

Legend for Supplementary Figures from Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma

Supplementary Figures 1-9, Supplementary Table 1 from Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib

Supplementary Figure 2 from Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1–MAPK Interaction

Supplementary Figure Legends from Mir-124 Inhibits STAT3 Signaling to Enhance T Cell–Mediated Immune Clearance of Glioma

Additional File 14 of M6a Eraser FTO Impairs Gemcitabine Resistance in Pancreatic Cancer Through Influencing NEDD4 Mrna Stability by Regulating the PTEN/PI3K/AKT Pathway

Supplementary Data from CDK4/6 Inhibition Enhances Oncolytic Virus Efficacy by Potentiating Tumor-Selective Cell Killing and T-cell Activation in Refractory Glioblastoma

Supplementary Data from Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response

Supplementary Figure S3 from Protein Kinase B (PKB/AKT) Protects IDH-Mutated Glioma from Ferroptosis Via Nrf2

Supplementary Table S2 from Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1–MAPK Interaction

Supplementary Data from Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma

Supplementary Data from Fimepinostat Impairs NFκB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma

Data from Fimepinostat Impairs NFκB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma

Fimepinostat impairs NFκB and PI3K/AKT signaling and enhances gemcitabine efficacy in H3K27M-mutated diffuse intrinsic pontine glioma